Drug Research
Long-Awaited Daxxify By Revance Will Compete With Botox
Revance Therapeutics may soon run into an identity problem with a product that is so eagerly awaited that some people mistakenly call it by the name of the firm. Daxxify, Revance's long-awaited Botox rival, has officially received FDA approval,...
Clinical Trials
Trodelvy Breast Cancer Drug Makes A Spectacular Comeback
After unimpressive evidence on tumour progression, many Gilead Sciences investors have stopped believing in Trodelvy in HR-positive, HER2-negative breast cancer. But now that the antibody-drug combination has unexpectedly returned, blockbuster dreams have been rekindled thanks to a life extension...
News
3 Unusual Foods and Drinks You Should Try at Least Once
If you are a total foodie and you’re looking for some inspiration, you’ve come to the right place. Food trends made for the Gram may come and go, but unique food and drink items with a special story behind...
News
5 Ways AI Can Improve The Pharma Industry
Pharmaceuticals are a vital part of the healthcare industry. They help improve the quality of drugs and services they provide, as well as discover new drugs to cure deadly and complicated diseases. That said, it's crucial to streamline their...
Drug Research
Introduction of Anti-Evolocumab Antibodies From Bio-Rad
A group of type 1 antibodies recently made available by Bio-Rad Laboratories are intended to prevent the drug evolcumab from attaching to its target, human proprotein convertase subtilisin/kexin type 9. (PCSK9). These recombinant, sequence-defined antibodies are meant to create...
News
For $1.1 Billion, Novo Nordisk To Buy Forma Therapeutics
On September 1, 2022, Novo Nordisk and Forma Therapeutics revealed that Novo Nordisk would buy Forma Therapeutics for for $1.1 billion. With the purchase of Forma, Novo Nordisk now has access to the company's inventory of sickle cell disease...
Drug Research
Merck Assesses 5 Years of Keytruda Lung Cancer Research
By demonstrating a massive survival benefit, Keytruda's Keynote-189 study precipitated a turning point in the development of lung cancer medications. Merck & Co. is now providing a five-year review of the data that rendered the PD-1 inhibitor the norm...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read